| Accession |
PRJCA023278 |
| Title |
Evaluation of PD-L1/TGF-βRII antibodies in combination with gemcitabine and albumin-paclitaxel in first-line treatment of advanced/metastatic pancreatic cancer Phase Ib/II clinical Study (1701-204) |
| Relevance |
Medical |
| Data types |
Whole genome sequencing
Genome sequencing
includes metabolic, biomarker, data, etc
|
| Organisms |
Homo sapiens
|
| Description |
Evaluation of PD-L1/TGF-βRII Antibody (SHR-1701 injection) in combination with gemcitabine and albumin-paclitaxel in first-line treatment of advanced/metastatic pancreatic cancer Phase Ib/II clinical Study (SHR-1701-204) |
| Sample scope |
Multiisolate |
| Release date |
2024-01-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| na
|
|
na
|
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2024-01-29 |
